REGN
Regeneron Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
818.77
close · 2026-10-29
value
68
cheaper than peers68
quality
89
stronger fundamentals89
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 5.26× | 72 |
| forward P/E | 13.03× | 70 |
| price to book | 2.59× | 63 |
| EV to EBITDA | 14.76× | 51 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 20.7% | 88 |
| return on equity | 14.5% | 85 |
| debt to equity | 8.6% | 64 |
| revenue growth | 19.0% | 50 |
4 of 4 measures available
Facts
| market cap | $84B |
| free cash flow | $3.27B |
| employees | 15,343 |
| first trade | 1991-04-02 |
| next earnings | 2026-10-30 |
| fundamentals updated | 2026-07-31 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 41.48 | 38.34 | 34.77 | 38.22 |
| free cash flow | $3.77B | $3.54B | $3.67B | $3.40B |
| net income | $4.50B | $4.41B | $3.95B | $4.34B |
| revenue | $14.34B | $14.20B | $13.12B | $12.17B |
| unusual items | $822.0M | $17.3M | -$452.5M | -$244.7M |